-
Fully remote Colorado PharmD program earns accreditation
The fully remote PharmD program at University of Colorado Skaggs School of Pharmacy and Pharmaceutical Science in Aurora has received full accreditation from the Accreditation Council for Pharmacy Education. -
The costliest hospital drugs for infectious diseases
Hospitals spent about 7% of annual pharmaceutical spend on infectious disease treatments, according to a Vizient report released July 30. -
15 most expensive medications for Vizient customers
Health systems spent 77% more on semaglutide, the active ingredient of Ozempic and Wegovy, between April 2023 and March 2024, compared to the prior year, according to Vizient's Pharmacy Market Outlook. -
Appetite grows for mail-order pharmacies: Study
Patients are becoming less satisfied with physical pharmacies as popularity rises for online and mail-order services, according to J.D. Power's 16th annual U.S. Pharmacy Study. -
The priciest hospital drugs for 8 service lines
Between April 2023 and March 2024, Humira accounted for top medication spend for Vizient pharmacy program participants, according to a Vizient report published July 30. -
8 drugs now in shortage
In the second quarter of 2024, there were 300 medications in shortage across the U.S. -
California system eyes internal pharmacy opportunities with partnership
Loma Linda (Calif.) University Health is collaborating with data analytics firm Loopback Analytics to level up the health system's specialty pharmacy services. -
Another US drugmaker on the verge of closure: Report
A generic drugmaker likely will shut down if it does not receive federal assistance, The Wall Street Journal reported July 26. -
Not a booster: 4 notes on fall COVID vaccines
Epidemiologists and virologists are moving away from the term "booster" to describe COVID-19 vaccines, according to a July 26 ABC News report. -
FDA warns of dosing errors tied to compounded Ozempic, Wegovy
The FDA is warning healthcare providers of dosing errors associated with compounded versions of semaglutide, the active ingredient in Ozempic, Rybelsus and Wegovy. -
7 updates on GLP-1s
Ozempic and other GLP-1 medications are increasingly affecting hospital operations and the U.S. healthcare industry. -
Walmart opens 25 new 'autoimmune-focused' pharmacies
Walmart has opened 25 new autoimmune-focused specialty pharmacies across the U.S. -
HHS, Walgreens partner on 1st decentralized COVID shot trial
Walgreens has received $25 million in federal funding to conduct a decentralized clinical trial on COVID-19 vaccine immunity. -
25-person obesity pill trial earns drugmaker $16.8B
On July 17, Roche published early results from a phase 1 trial of an experimental GLP-1 pill for obesity. That day, the drugmaker gained $16.8 billion in its market value, Bloomberg reported. -
Support grows for expanding pharmacist scopes
Compared to a year prior, more pharmacists, physicians, physician assistants and nurse practitioners agree that pharmacists should have more primary care duties, according to a survey conducted by Surescripts. -
Hikma recalls IV bags
On July 22, Hikma Pharmaceuticals announced a voluntary recall of one lot of intravenous bags after a reported adverse event. -
House criticizes PBMs for pushing patients to higher-priced drugs
An investigation by federal lawmakers found that pharmacy-benefit managers promised to control costs but have instead steered patients toward higher-priced medicines and affiliated pharmacies that reduce patient choice, The Wall Street Journal reported July 23. -
Endo recalls mislabeled drug lot
Endo USA is voluntarily recalling one lot of clonazepam because of mislabeled strength information, the FDA said July 17. -
What 14 pharmacy chiefs will prioritize for the next 6 months
Becker's asked chief pharmacy officers from hospitals and health systems across the U.S. to share their focus for the remainder of the year. -
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
Drugmakers Pfizer and Valneva are one step closer to obtaining FDA approval for what would be the first Lyme disease vaccine after publishing positive results from a phase 3 trial, the companies announced July 17.
Page 11 of 50